Trial · NCT02049814
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Urinary tract infection | Infections and infestations | Metformin + Voglibose 0.2 mg | 15 | 248 | |
| other | Urinary tract infection | Infections and infestations | Metformin + Acarbose 50 mg | 9 | 245 | |
| other | Flatulence | Gastrointestinal disorders | Metformin + Voglibose 0.2 mg | 23 | 248 | |
| other | Flatulence | Gastrointestinal disorders | Metformin + Acarbose 50 mg | 41 | 245 | |
| serious | Sudden hearing loss | Ear and labyrinth disorders | Metformin + Voglibose 0.2 mg | 1 | 248 | |
| serious | Sudden hearing loss | Ear and labyrinth disorders | Metformin + Acarbose 50 mg | 0 | 245 | |
| serious | ALT increased | Investigations | Metformin + Voglibose 0.2 mg | 0 | 248 | |
| serious | ALT increased | Investigations | Metformin + Acarbose 50 mg | 1 | 245 | |
| serious | Abnormal liver function test | Investigations | Metformin + Voglibose 0.2 mg | 1 | 248 | |
| serious | Abnormal liver function test | Investigations | Metformin + Acarbose 50 mg | 0 | 245 | |
| serious | Cerebral ischemia | Nervous system disorders | Metformin + Voglibose 0.2 mg | 1 | 248 | |
| serious | Cerebral ischemia | Nervous system disorders | Metformin + Acarbose 50 mg | 0 | 245 | |
| serious | Cerebral hemangioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Metformin + Voglibose 0.2 mg | 0 | 248 | |
| serious | Cerebral hemangioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Metformin + Acarbose 50 mg | 1 | 245 | |
| serious | Hepatic tumor | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Metformin + Voglibose 0.2 mg | 0 | 248 | |
| serious | Hepatic tumor | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Metformin + Acarbose 50 mg | 1 | 245 | |
| serious | Local swelling | General disorders | Metformin + Voglibose 0.2 mg | 0 | 248 | |
| serious | Local swelling | General disorders | Metformin + Acarbose 50 mg | 1 | 245 | |
| serious | Acute coronary syndrome | Cardiac disorders | Metformin + Voglibose 0.2 mg | 0 | 248 | |
| serious | Acute coronary syndrome | Cardiac disorders | Metformin + Acarbose 50 mg | 1 | 245 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02049814/events